替加环素治疗颅内多重耐药革兰氏阴性杆菌感染研究进展  

Research progress of tigecycline in the treatment of intracranial infection caused by multidrug resistant Gram-negative bacilli

作　　者：范星岳 侯雅琴 贾旭 FAN Xingyue;HOU Yaqin;JIA Xu(Department of Pharmacy,Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan Province,China)

机构地区：[1]川北医学院附属医院药剂科,四川南充637000

出　　处：《世界临床药物》2025年第2期196-202,共7页World Clinical Drug

基　　金：川北医学院校级科研发展基金项目(CBY21-QA34);川北医学院附属医院科研发展计划项目(2022JC029)。

摘　　要：颅内多重耐药革兰氏阴性杆菌感染是临床治疗的难题。替加环素(tigecycline)作为一种新型抗生素,展现出对抗多重耐药革兰氏阴性杆菌的潜力,成为治疗颅内感染的重要选择。该文综述替加环素治疗颅内感染的研究进展,包括其抗菌机制、药动学特征及治疗有效性等;同时指出替加环素治疗的安全性需进一步验证。建议在临床实践中通过个体化治疗、联合用药及药学监护评估等方案最大程度地减少替加环素治疗颅内感染时的潜在风险,平衡疗效与安全性,实现治疗最优化。Intracranial infections caused by multidrug-resistant Gram-negative bacteria is a difficult problem in clinical treatment.Tigecycline,a novel antibiotic,has demonstrated potential against multidrug-resistant Gram-negative bacteria and has become an important option for treating intracranial infections.This article reviewed the research progress of tigecycline in treating intracranial infections,including its antimicrobial mechanism,pharmacokinetic characteristics,and therapeutic efficacy.It also pointed out that the safety of tigecycline treatment needed further verification.It was recommended to minimize the potential risks of tigecycline in the treatment for intracranial infections,balance the efficacy and safety,and achieve optimal treatment through individualized treatment plans,combination therapy,pharmaceutical monitoring and evaluation in clinical practice.

关 键 词：替加环素 颅内感染 多重耐药革兰氏阴性杆菌 

分 类 号：R978.14[医药卫生—药品]